Cost-effectiveness of QuantiFERON-TB Gold In-Tube versus tuberculin skin test for diagnosis and treatment of Latent Tuberculosis Infection in primary health care workers in Brazil.

Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE

Original Publication: San Francisco, CA : Public Library of Science

Cost-Benefit Analysis* ; Health Personnel* ; Primary Health Care*; Latent Tuberculosis/*epidemiology ; Tuberculin Test/*methods; Adult ; Aged ; Clinical Decision-Making ; Decision Trees ; Female ; Humans ; Latent Tuberculosis/diagnosis ; Latent Tuberculosis/therapy ; Male ; Mass Screening/economics ; Mass Screening/methods ; Middle Aged ; Reproducibility of Results ; Sensitivity and Specificity ; Tuberculin Test/economics ; Tuberculin Test/standards ; Young Adult

Objectives: The goal of this study was to perform a cost-effectiveness analysis from the public health system perspective, comparing five strategies for Latent Tuberculosis Infection (LTBI) diagnosis in primary health care workers in Brazil.
Design: Analytical model for decision making, characterized by cost-effectiveness analysis.
Setting: Primary Care Level, considering primary health care workers in Brazil.
Participants: An analytical model for decision making, characterized by a tree of probabilities of events, was developed considering a hypothetical cohort of 10,000 primary health care workers, using the software TreeAge Pro™ 2013 to simulate the clinical and economic impacts of new diagnostic technology (QuantiFERON®-TB Gold in-Tube) versus the traditional tuberculin skin test.
Methods: This model simulated five diagnostic strategies for LTBI in primary health care workers (HCW) in Brazil: tuberculin skin testing using ≥5 mm cut-off, tuberculin skin testing ≥10 mm cut-off, QuantiFERON®-TB Gold in-Tube, tuberculin skin testing using ≥5 mm cut-off confirmed by QuantiFERON®-TB Gold In-Tube if TST positive, tuberculin skin testing using ≥10 mm cut-off confirmed by QuantiFERON®-TB Gold In-Tube if TST positive.
Primary and Secondary Outcome Measures: The outcome measures are the number of individuals correctly classified by the test and the number of Tuberculosis cases avoided.
Results: The most cost-effective strategy was the tuberculin skin test considering ≥10mm cut-off. The isolated use of the QuantiFERON®-TB Gold In-Tube revealed the strategy of lower efficiency with incremental cost-effectiveness ratio (ICER) of US$ 146.05 for each HCW correctly classified by the test.
Conclusions: The tuberculin skin test using ≥10 mm cut-off was the most cost-effective strategy in the diagnosis of Latent Tuberculosis Infection in primary health care works in Brazil.
Competing Interests: The authors have declared that no competing interests exist. This study has not been submitted elsewhere for publication. All authors have approved the manuscript.

Infect Control Hosp Epidemiol. 2008 Sep;29(9):878-86. (PMID: 18713053)
Am J Respir Crit Care Med. 2006 Oct 15;174(8):935-52. (PMID: 17021358)
Chest. 2005 Jul;128(1):116-23. (PMID: 16002924)
Am J Respir Crit Care Med. 2006 Aug 1;174(3):349-55. (PMID: 16690977)
Am J Respir Crit Care Med. 2003 Aug 15;168(4):412-3. (PMID: 12912731)
Infect Control Hosp Epidemiol. 2001 Feb;22(2):88-93. (PMID: 11232884)
PLoS Med. 2016 Oct 25;13(10):e1002152. (PMID: 27780211)
Int J Tuberc Lung Dis. 2010 Apr;14(4):471-81. (PMID: 20202306)
BMC Health Serv Res. 2011 Sep 30;11:247. (PMID: 21961888)
Int J Tuberc Lung Dis. 2001 Jun;5(6):583-4. (PMID: 11409589)
Bull World Health Organ. 1982;60(4):555-64. (PMID: 6754120)
Can Commun Dis Rep. 2008 Oct;34(ACS-6):1-13. (PMID: 18979589)
PLoS Med. 2007 Jun;4(6):e208. (PMID: 17564491)
J Bras Pneumol. 2009 Oct;35(10):1018-48. (PMID: 19918635)
Ann Intern Med. 1997 Dec 15;127(12):1051-61. (PMID: 9412307)
BMC Pulm Med. 2010 Feb 22;10:7. (PMID: 20170555)
Eur Respir J. 2006 Jul;28(1):24-30. (PMID: 16611658)
MMWR Recomm Rep. 2000 Jun 9;49(RR-6):1-51. (PMID: 10881762)
Am J Respir Crit Care Med. 1996 Sep;154(3 Pt 1):587-93. (PMID: 8810591)
Arch Intern Med. 2009 Jan 26;169(2):179-87. (PMID: 19171815)
Infect Control Hosp Epidemiol. 2006 May;27(5):442-8. (PMID: 16671023)
J Rheumatol. 2008 May;35(5):776-81. (PMID: 18398944)
Epidemiol Infect. 1997 Oct;119(2):183-201. (PMID: 9363017)
Clin Infect Dis. 2005 Jan 15;40(2):211-7. (PMID: 15655737)
Jpn J Infect Dis. 2007 May;60(2-3):102-5. (PMID: 17515641)
JAMA. 2005 Jun 8;293(22):2746-55. (PMID: 15941804)
Clin Infect Dis. 1993 Dec;17(6):968-75. (PMID: 8110954)
Chest. 2007 May;131(5):1424-34. (PMID: 17494792)
J Infect Dis. 2011 Nov 15;204 Suppl 4:S1120-9. (PMID: 21996694)
J Infect Dis. 2002 Dec 15;186(12):1797-807. (PMID: 12447766)
Clin Infect Dis. 1995 Nov;21(5):1098-101. (PMID: 8589127)
Lung. 2009 Nov-Dec;187(6):413-9. (PMID: 19830489)
Am J Respir Crit Care Med. 2003 Aug 15;168(4):443-7. (PMID: 12746255)
Ann Intern Med. 1995 Jan 15;122(2):90-5. (PMID: 7993001)
MMWR Recomm Rep. 2005 Dec 30;54(RR-17):1-141. (PMID: 16382216)
Bull World Health Organ. 1972;46(3):371-85. (PMID: 4537855)
Infect Control Hosp Epidemiol. 2002 Oct;23(10):584-90. (PMID: 12400887)
N Engl J Med. 2002 Dec 5;347(23):1850-9. (PMID: 12466510)
Thorax. 2012 Jan;67(1):62-70. (PMID: 21228420)
Ann Intern Med. 2008 Aug 5;149(3):177-84. (PMID: 18593687)
Int J Tuberc Lung Dis. 2010 May;14(5):551-9. (PMID: 20392347)
Clin Microbiol Infect. 2011 Jun;17(6):806-14. (PMID: 21682801)
Int J Tuberc Lung Dis. 2011 Sep;15(9):1223-30, i. (PMID: 21943850)
Int J Tuberc Lung Dis. 1999 May;3(5):377-81. (PMID: 10331725)
J Hosp Infect. 2015 Feb;89(2):99-108. (PMID: 25559158)
Lancet. 2011 May 7;377(9777):1588-98. (PMID: 21492926)
Eur Respir J. 2011 Mar;37(3):690-711. (PMID: 20693257)
Int J Tuberc Lung Dis. 1999 Oct;3(10):847-50. (PMID: 10524579)
Chest. 1991 Feb;99(2):465-71. (PMID: 1824929)
JAMA. 2005 Jun 8;293(22):2767-75. (PMID: 15941807)
N Engl J Med. 2002 Dec 5;347(23):1860-6. (PMID: 12466511)
MMWR Recomm Rep. 2003 Jan 31;52(RR-2):15-8. (PMID: 12583541)
Eur Respir J. 2011 Jan;37(1):88-99. (PMID: 21030451)
J Acquir Immune Defic Syndr. 2011 Mar 1;56(3):230-8. (PMID: 21239993)
Lancet. 2006 Apr 22;367(9519):1328-34. (PMID: 16631911)
Int J Tuberc Lung Dis. 2005 Dec;9(12):1335-42. (PMID: 16466055)
West J Med. 1996 Jun;164(6):486-91. (PMID: 8764622)
Healthc Financ Manage. 1998 Aug;52(8):66-70. (PMID: 10182280)
JAMA. 1999 Mar 17;281(11):1014-8. (PMID: 10086436)
Int Arch Occup Environ Health. 2008 Jan;81(3):295-300. (PMID: 17605033)
PLoS One. 2013 Apr 04;8(4):e59546. (PMID: 23593145)
Ann Intern Med. 2007 Mar 6;146(5):340-54. (PMID: 17339619)
Am J Respir Crit Care Med. 2005 Sep 1;172(5):631-5. (PMID: 15961696)
Int J Tuberc Lung Dis. 2008 Dec;12(12):1414-24. (PMID: 19017451)
Lancet. 2012 May 19;379(9829):1902-13. (PMID: 22608339)
Inflamm Bowel Dis. 2012 Nov;18(11):2034-42. (PMID: 22294550)
Lancet. 2000 Sep 23;356(9235):1099-104. (PMID: 11009160)
Am J Respir Crit Care Med. 2004 Jul 1;170(1):5-6. (PMID: 15220119)
Am J Respir Crit Care Med. 2011 Sep 1;184(5):590-601. (PMID: 21562129)
Chest. 2010 Apr;137(4):952-68. (PMID: 20022968)
Chest. 2009 Apr;135(4):1010-1018. (PMID: 19017873)
Chest. 2010 Feb;137(2):401-9. (PMID: 19793865)

Date Created: 20191115 Date Completed: 20200324 Latest Revision: 20200324

20240105

PMC6855475

10.1371/journal.pone.0225197

31725786